Clinical Trial Update: Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neratinib (HKI-272) in subjects with advanced non-small cell lung cancer has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2018-04-13